Episode
Enhanced Group CEO: Hot peptide summer is coming — but likely not till 2027
- Podcast
- Hims House
- Published
- Aug 7, 2026
- Duration seconds
- 3266
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/enhanced-group-ceo-hot-peptide-summer-is-coming-but-likely-not-till-2027/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hims-house-7026583/enhanced-group-ceo-hot-peptide-summer-is-coming-but-likely-not-till-2027.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Max's recent essays on peptides: https://maximilianbmartin.substack.com/p/six-peptides-one-signal-washington https://maximilianbmartin.substack.com/p/the-peptide-moment-is-here-enhanced In episode 76 of Hims House, Jonathan Stern hosts Maximilian Martin, CEO of Enhanced Group ( $ENHA ), the newly public company behind the Enhanced Games and the Live Enhanced telehealth platform. Martin grades the inaugural games ten weeks out — 42 athletes, 21 personal bests, one world record, and $32M in contracted sponsorship — and argues the 40% stock price selloff that occurred after the Games is misplaced. He recounts his week in Washington D.C., around the FDA compounding advisory committee, where six of seven peptides were recommended, and explains why Enhanced will wait on FDA’s formal rulemaking to start selling peptides. He concedes peptides are essentially a “commodity”, so the edge has to come from brand and personalized protocols. Also covered: whether big pharma is quietly slowing things down, how big the market for peptides could be, and Enhanced’s recent supplements launch in 33 new countries. 00:00 - Sponsor: Superpower 01:38 - The Enhanced Games: an honest scorecard 06:35 - Why $ENHA stock fell 40% 10:13 - The athlete-led flywheel 11:52 - Why he flew to Washington for peptides 18:07 - Six of seven peptides recommended 20:21 - How long will FDA rulemaking take? 22:51 - Where the peptide moat actually is 30:16 - Is big pharma slowing down peptide approval? 32:14 - Being first vs being best 40:33 - Could peptides be a $10B market in 2027? 46:00 - Enhanced now live in 33 new markets 50:25 - Life as a public company CEO Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advic…